Press Release Indee Labs announces an exclusive marketing and distribution deal with Sunko Instruments in China for Hydropore.

Press Release Transforming Biotech R&D: Indee Labs Leverages Scispot's Digital Platform for Enhanced Efficiency, Compliance and Automation

Press Release — Indee Labs to complete the development and launch of Hydropore RUO and Cell Therapy along with a direct DNA knock-in kit, enabled by BroadOak's strategic investment and domain expertise.

Press Release — Indee Labs’ research collaboration with GenScript aims to develop a DNA knock-in kit for Hydropore™ to enable large transgene inserts above the 5 kb limit for AAV

Press Release — Indee Labs partners with Monomer Bio to automate Hydropore workflows for engineered T cells and similar immune cell types.

Press Release — Indee Labs announces a $2M contract with the National Cancer Institute to scale up and out the Hydropore^TM platform for cell therapy with Eyquem Lab at UCSF.

Featured by Medical University of South Carolina — MUSC Hollings Cancer Center researcher Leonardo Ferreira, Ph.D., and Indee Labs recently received a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Small Business Innovation Research (SBIR) grant to accelerate the development of human T-cell therapies.

Press Release — Indee Labs today announced the addition of three of the largest pharmaceutical companies, multiple biotechnology companies as well as Stanford's Cell Therapy Clinic and Moffitt Cancer Center, to participate in its Early Access Program.

Press Release — The team at Indee Labs was recently awarded a contract from the National Cancer Institute to develop the µVS Delivery System^TM to insert transgenes for CAR-T and TCR-T cell products at clinical scale at a fraction of the cost of the current approaches using viruses with improved T cell function relative to electroporation.

Press Release — With funding from NIAID, our goal is to apply our novel, non-viral delivery platform, the µVS Delivery System^TM, to engineer antigen-specific T_regs and demonstrate their utility as a therapeutic to prevent GvHD in preclinical models and as a scalable alternative to viral- and electroporation-based cell manufacturing.

Featured in Synthego — In this interview, we chatted with Ryan about the concept of using microfluidics for CRISPR delivery, the mission and ongoing projects at Indee Labs, and the convergence of engineering and biology for building scalable platforms.